City

Cleveland (2)

Boston (1)

Duarte (1)

Houston (1)

New York (1)

Orange (1)

Seattle (1)

Stanford (1)

Tuebingen (1)

Overall Status

Recruiting (2)

Completed (1)

Phase

phase 1/phase 2 (2)

phase 2 (1)

Sponsor

Mustang Bio (1)

Precision BioSciences, Inc. (1)

University Hospital Tuebingen (1)

Collaborator

GlaxoSmithKline (1)

National Cancer Institute (NCI) (1)

Intervention

belimumab 200 mg/ml [benlysta] (1)

cyclophosphamide (1)

fludarabine (1)

mb-106 (1)

pbcar20a (1)

standard of care (1)

Study Documents

Intervention Type

drug (2)

biological (1)

genetic (1)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (3)

chronic lymphoid leukemia in relapse

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States

Completed

Has Results

Non-Hodgkin's Lymphoma, Relapsed
+8 more

PBCAR20A
+2 more

Duarte, California
+4 more

Jan 4, 2023

Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory Trial in Orange,

Recruiting

Follicular B-cell Non-Hodgkin's Lymphoma
+7 more

MB-106

Orange, California
+3 more

Nov 1, 2022

Chronic Lymphoid Leukemia in Relapse Trial in Tuebingen (Belimumab 200 MG/ML [Benlysta], standard of care)

Recruiting

Chronic Lymphoid Leukemia in Relapse

Belimumab 200 MG/ML [Benlysta]
standard of care

Tuebingen, BW, Germany

University Hospital Tuebingen, CCU Translational Immunology

Feb 2, 2022